SI3220947T1 - Protitelesa, ki močno nevtralizirajo virus stekline in druge lisaviruse in njihove uporabe - Google Patents

Protitelesa, ki močno nevtralizirajo virus stekline in druge lisaviruse in njihove uporabe

Info

Publication number: SI3220947T1
Authority: SI; Slovenia
Prior art keywords: lyssaviruses; antibodies; rabies virus; potently neutralize; neutralize rabies
Prior art date: 2014-11-18

Application number

SI201531420T

Other languages

English (en)

Inventor

Davide Corti

Herve Bourhy

Original Assignee

Humabs Biomed S.A.

Institut Pasteur

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-11-18

Filing date

2015-11-18

Publication date

2021-02-26

2015-11-18 Application filed by Humabs Biomed S.A., Institut Pasteur filed Critical Humabs Biomed S.A.

2021-02-26 Publication of SI3220947T1 publication Critical patent/SI3220947T1/sl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Mycology (AREA)
Engineering & Computer Science (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

SI201531420T 2014-11-18 2015-11-18 Protitelesa, ki močno nevtralizirajo virus stekline in druge lisaviruse in njihove uporabe SI3220947T1 (sl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP2014003076		2014-11-18
EP15798327.1A EP3220947B1 (en)	2014-11-18	2015-11-18	Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof
PCT/EP2015/002305 WO2016078761A1 (en)	2014-11-18	2015-11-18	Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof

Publications (1)

Publication Number	Publication Date
SI3220947T1 true SI3220947T1 (sl)	2021-02-26

Family

ID=52339085

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI201531420T SI3220947T1 (sl)	2014-11-18	2015-11-18	Protitelesa, ki močno nevtralizirajo virus stekline in druge lisaviruse in njihove uporabe

Country Status (13)

Country	Link
US (4)	US10703801B2 (sl)
EP (2)	EP3831404A1 (sl)
CN (2)	CN107428819B (sl)
BR (2)	BR122020023406B1 (sl)
DK (1)	DK3220947T3 (sl)
ES (1)	ES2838679T3 (sl)
HR (1)	HRP20201811T1 (sl)
HU (1)	HUE052595T2 (sl)
LT (1)	LT3220947T (sl)
PH (2)	PH12017500722B1 (sl)
PL (1)	PL3220947T3 (sl)
SI (1)	SI3220947T1 (sl)
WO (1)	WO2016078761A1 (sl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2019227039A1 (en) *	2018-05-24	2019-11-28	Lankenau Institute For Medical Research	Compositions comprising antibodies to rabies virus and the uses thereof
WO2020078568A1 (en) *	2018-10-19	2020-04-23	Humabs Biomed Sa	Antibodies and methods for treatment of lyssavirus infection
EP3873526B1 (en) *	2018-11-02	2024-09-04	Zydus Lifesciences Limited	Anti-rabies monoclonal antibodies and cocktail thereof
CN109970852B (zh) *	2019-04-01	2020-10-13	浙江大学	分泌抗狂犬病毒m蛋白单克隆抗体的杂交瘤细胞株及应用
WO2021055614A1 (en) *	2019-09-17	2021-03-25	Auburn University	Antibody gene therapy for treatment and prevention of infection by rabies lyssavirus
WO2022090484A2 (en) *	2020-10-29	2022-05-05	The Secretary Of State For Environment, Food And Rural Affairs	Viral vector
CN114958774B (zh) *	2022-05-08	2023-10-27	中国医学科学院医学生物学研究所	抗狂犬病病毒单克隆抗体及分泌该抗体的杂交瘤细胞株与应用
CN117683123A (zh) *	2023-09-15	2024-03-12	东普安凤(北京)生物技术有限公司	抗狂犬病毒人源化抗体和抗体组合及其用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL154600B (nl)	1971-02-10	1977-09-15	Organon Nv	Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en)	1971-05-14	1974-06-18	Syva Corp	Enzyme amplification assay
US3766162A (en)	1971-08-24	1973-10-16	Hoffmann La Roche	Barbituric acid antigens and antibodies specific therefor
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
US4233402A (en)	1978-04-05	1980-11-11	Syva Company	Reagents and method employing channeling
JPS5896026A (ja)	1981-10-30	1983-06-07	Nippon Chemiphar Co Ltd	新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
DE3380726D1 (en)	1982-06-24	1989-11-23	Japan Chem Res	Long-acting composition
US4766106A (en)	1985-06-26	1988-08-23	Cetus Corporation	Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
US4831175A (en)	1986-09-05	1989-05-16	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5595721A (en)	1993-09-16	1997-01-21	Coulter Pharmaceutical, Inc.	Radioimmunotherapy of lymphoma using anti-CD20
MY133346A (en)	1999-03-01	2007-11-30	Biogen Inc	Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en)	1999-03-01	2002-08-01	Paul Chinn	Radiolabeling kit and binding assay
EP1597280B2 (en)	2003-02-26	2016-08-24	Institute for Research in Biomedicine	Monoclonal antibody production by ebv transformation of b cells
BRPI0606790C8 (pt)	2005-02-02	2021-05-25	Ct Disease Contr & Prevention	anticorpo monoclonal humano isolado ou porção de ligação de antígeno do mesmo, composição, vetor de expressão, microrganismo transgênico, célula hospedeira procariótica, kit, e, uso de um anticorpo monoclonal humano isolado ou porção de ligação de antígeno do mesmo, ou de uma composição
JP5837820B2 (ja)	2008-10-22	2015-12-24	インスティテュート・フォー・リサーチ・イン・バイオメディシンＩｎｓｔｉｔｕｔｅＦｏｒＲｅｓｅａｒｃｈＩｎＢｉｏｍｅｄｉｃｉｎｅ	形質細胞から抗体を産生する方法
WO2011080765A2 (en)	2010-01-04	2011-07-07	Indian Immunologicals Limited	Recombinant human bivalent diabody against rabies virus and uses thereof
EP2630242B1 (en) *	2010-10-19	2017-08-02	The Government of the United States of America as Represented by the Secretary of the Department of Health and Human Services,	Identification of antibodies specific for lyssaviruses
EP2855521A4 (en) *	2012-05-24	2016-03-02	Mountgate Group Ltd	COMPOSITIONS AND METHODS ASSOCIATED WITH THE PREVENTION AND TREATMENT OF RABIC INFECTION

2015
- 2015-11-18 EP EP20200023.8A patent/EP3831404A1/en active Pending
- 2015-11-18 CN CN201580073641.2A patent/CN107428819B/zh active Active
- 2015-11-18 ES ES15798327T patent/ES2838679T3/es active Active
- 2015-11-18 EP EP15798327.1A patent/EP3220947B1/en active Active
- 2015-11-18 WO PCT/EP2015/002305 patent/WO2016078761A1/en active Application Filing
- 2015-11-18 DK DK15798327.1T patent/DK3220947T3/da active
- 2015-11-18 BR BR122020023406-7A patent/BR122020023406B1/pt active IP Right Grant
- 2015-11-18 US US15/527,511 patent/US10703801B2/en active Active
- 2015-11-18 PL PL15798327T patent/PL3220947T3/pl unknown
- 2015-11-18 CN CN202210166356.7A patent/CN114805558B/zh active Active
- 2015-11-18 HU HUE15798327A patent/HUE052595T2/hu unknown
- 2015-11-18 SI SI201531420T patent/SI3220947T1/sl unknown
- 2015-11-18 BR BR112017010298-6A patent/BR112017010298B1/pt active IP Right Grant
- 2015-11-18 PH PH1/2017/500722A patent/PH12017500722B1/en unknown
- 2015-11-18 LT LTEP15798327.1T patent/LT3220947T/lt unknown
2020
- 2020-05-22 US US16/882,354 patent/US11730813B2/en active Active
- 2020-05-22 US US16/882,359 patent/US11723977B2/en active Active
- 2020-11-13 HR HRP20201811TT patent/HRP20201811T1/hr unknown
2021
- 2021-03-10 PH PH12021550521A patent/PH12021550521A1/en unknown
2023
- 2023-08-22 US US18/454,011 patent/US20240050565A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DK3220947T3 (da)	2020-11-30
US11723977B2 (en)	2023-08-15
ES2838679T3 (es)	2021-07-02
CN107428819B (zh)	2022-03-15
EP3220947B1 (en)	2020-10-28
PH12017500722B1 (en)	2022-08-05
CN114805558A (zh)	2022-07-29
HRP20201811T1 (hr)	2021-01-08
BR112017010298B1 (pt)	2023-10-31
CN107428819A (zh)	2017-12-01
LT3220947T (lt)	2020-12-28
US20200354436A1 (en)	2020-11-12
WO2016078761A1 (en)	2016-05-26
CN114805558B (zh)	2023-12-29
PH12017500722A1 (en)	2017-10-09
PL3220947T3 (pl)	2021-05-31
US20180105579A1 (en)	2018-04-19
HUE052595T2 (hu)	2021-05-28
US11730813B2 (en)	2023-08-22
BR112017010298A2 (pt)	2017-12-19
EP3220947A1 (en)	2017-09-27
US20200354435A1 (en)	2020-11-12
EP3831404A1 (en)	2021-06-09
US10703801B2 (en)	2020-07-07
US20240050565A1 (en)	2024-02-15
BR122020023406B1 (pt)	2023-10-31
PH12021550521A1 (en)	2022-02-14

Publication	Publication Date	Title
HK1257480A1 (zh)	2019-10-18	工程病毒
HK1256869A1 (zh)	2019-10-04	強力地中和乙型肝炎病毒的抗體和其用途
HK1255067A1 (zh)	2019-08-02	抗c10orf54抗體及其用途
HK1243440A1 (zh)	2018-07-13	抗白細胞介素-33抗體及其用途
IL247407A0 (en)	2016-11-30	Antibodies against egfrviii and their uses
IL249184B (en)	2022-04-01	Anti-TNF-alpha glycoantibodies and their uses
IL286265A (en)	2021-10-31	A new tilapia virus and its uses
GB201406608D0 (en)	2014-05-28	Virus
IL282201B (en)	2022-04-01	Anti-tensin c antibodies and their uses
PL3220947T3 (pl)	2021-05-31	Przeciwciała silnie neutralizujące wirusa wścieklizny i inne lyssawirusy oraz ich zastosowanie
IL251001B (en)	2021-04-29	Anti-il-25 antibodies and their uses
HK1250482A1 (zh)	2018-12-21	針對狂犬病的人抗體及其用途
GB201419572D0 (en)	2014-12-17	Virus
SG11201609908VA (en)	2016-12-29	Virus reduction method
GB201600382D0 (en)	2016-02-24	Engineered virus
GB201600380D0 (en)	2016-02-24	Modified virus
GB201406470D0 (en)	2014-05-28	Virus
GB201403582D0 (en)	2014-04-16	Virus
GB201408046D0 (en)	2014-06-18	Virus preparations